US5672347A
(en)
*
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
IL73883A
(en)
*
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
JP3443119B2
(ja)
|
1989-08-07 |
2003-09-02 |
ペプテック リミテッド |
腫瘍壊死因子結合リガンド
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US6713610B1
(en)
*
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
GB9109645D0
(en)
*
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US20040120952A1
(en)
*
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US20050255104A1
(en)
*
|
1993-01-29 |
2005-11-17 |
Centocor, Inc. |
Methods of treating psoriasis using anti-TNF receptor fusion proteins
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
CN101712720A
(zh)
*
|
1996-02-09 |
2010-05-26 |
艾博特生物技术有限公司 |
结合人TNFα的人抗体
|
AU2013203420B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
AU2013257402B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
AU2012261708B2
(en)
*
|
1996-02-09 |
2014-02-20 |
Abbvie Biotechnology Ltd |
Human antibodies that bind human TNFalpha
|
KR20080059467A
(ko)
*
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
|
US7494652B1
(en)
|
1998-06-10 |
2009-02-24 |
Promega Corporation |
Treatment of sepsis
|
US6395273B1
(en)
|
1998-06-10 |
2002-05-28 |
Promega Corporation |
Prevention and treatment of inflammatory bowel disease
|
DE69901569T2
(de)
*
|
1998-08-28 |
2002-12-19 |
Genentech Inc |
Humane antikörper gegen faktor ix/ixa
|
DE60045240D1
(de)
*
|
1999-03-02 |
2010-12-30 |
Centocor Inc |
Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
NZ519222A
(en)
*
|
1999-12-14 |
2004-04-30 |
Genentech Inc |
TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
|
US20110195063A1
(en)
*
|
2000-08-07 |
2011-08-11 |
Centocor, Inc. |
Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
|
US20090081234A1
(en)
*
|
2000-08-07 |
2009-03-26 |
George Heavner |
Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20050249735A1
(en)
*
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
US20060018907A1
(en)
*
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
CN1547486A
(zh)
|
2001-06-26 |
2004-11-17 |
|
抗opgl抗体
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
KR20050042466A
(ko)
*
|
2002-07-19 |
2005-05-09 |
애보트 바이오테크놀로지 리미티드 |
TNFα 관련 질환의 치료
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
AU2003265361A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
JP2006519763A
(ja)
|
2002-11-08 |
2006-08-31 |
アブリンクス エン.ヴェー. |
治療用ポリペプチドの投与法およびそのためのポリペプチド
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
RU2377253C2
(ru)
*
|
2002-12-02 |
2009-12-27 |
Амген Фремонт,Инк. |
Антитела, специфичные к фактору некроза опухолей, и их применение
|
JP2006517191A
(ja)
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
EP1460088A1
(de)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
|
US20040185047A1
(en)
*
|
2003-03-21 |
2004-09-23 |
Jill Giles-Komar |
Anti- TNF antibodies, compositions, methods and uses
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
CA2573392A1
(en)
*
|
2004-07-12 |
2006-09-08 |
Rappaport Family Institute For Research In The Medical Sciences |
Methods of detecting a phenotype of a polymorphic protein
|
US20060083741A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Hoffman Rebecca S |
Treatment of respiratory syncytial virus (RSV) infection
|
DE602005026571D1
(de)
*
|
2004-12-29 |
2011-04-07 |
Yuhan Corp |
Tumornekrosefaktor-alpha spezifische humanisierte antikörper
|
CN101500607B
(zh)
|
2005-05-16 |
2013-11-27 |
阿布维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
CN105153306B
(zh)
*
|
2005-06-07 |
2020-12-11 |
艾斯巴技术-诺华有限责任公司 |
抑制TNFα的稳定和可溶的抗体
|
ATE470151T1
(de)
*
|
2005-08-02 |
2010-06-15 |
Xbiotech Inc |
Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
WO2007030930A1
(en)
*
|
2005-09-13 |
2007-03-22 |
National Research Council Of Canada |
Methods and compositions for modulating tumor cell activity
|
JP4861019B2
(ja)
*
|
2006-01-31 |
2012-01-25 |
独立行政法人科学技術振興機構 |
ヒトTNF−αに対する抗体酵素およびその利用
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
US20110008282A1
(en)
*
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
PL2109623T3
(pl)
*
|
2006-05-22 |
2012-03-30 |
Xbiotech Inc |
Leczenie nowotworu przeciwciałami przeciw il-1
|
AU2008205512B2
(en)
*
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
US8877186B2
(en)
*
|
2007-06-06 |
2014-11-04 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
EP2171451A4
(de)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
US20090038182A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Lans Maris J |
Footwear with built-in scale
|
EP2193145A4
(de)
|
2007-08-28 |
2011-05-18 |
Abbott Biotech Ltd |
Zusammensetzungen und verfahren mit bindungsproteinen für adalimumab
|
SG187473A1
(en)
|
2008-01-15 |
2013-02-28 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
WO2009097095A2
(en)
*
|
2008-01-28 |
2009-08-06 |
The Regents Of The University Of California |
Methods for treating hematopoietic malignancies
|
CN102027016A
(zh)
*
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
CA2718184A1
(en)
*
|
2008-03-13 |
2009-10-08 |
Biotest Ag |
Agent for treating disease
|
CN102027018A
(zh)
*
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
AU2009225797A1
(en)
|
2008-03-18 |
2009-09-24 |
Abbvie Inc. |
Methods for treating psoriasis
|
MY154067A
(en)
*
|
2008-05-30 |
2015-04-30 |
Xbiotech Inc |
IL-1a ABS AND METHODS OF USE
|
ES2687259T5
(es)
|
2008-06-25 |
2022-10-14 |
Novartis Ag |
Anticuerpos estables y solubles que inhiben TNF
|
JP5976319B2
(ja)
*
|
2008-09-12 |
2016-08-23 |
エックスバイオテク,インコーポレイテッドXbiotech,Inc. |
病原性単球の標的化
|
DK2341937T3
(en)
*
|
2008-09-29 |
2015-02-09 |
Biotest Ag |
Composition for the treatment of a disease
|
US8415291B2
(en)
*
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
NZ606283A
(en)
*
|
2008-11-28 |
2014-08-29 |
Abbvie Inc |
Stable antibody compositions and methods for stabilizing same
|
US8349325B2
(en)
|
2008-12-23 |
2013-01-08 |
Abbott Laboratories |
Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
|
AU2010291927A1
(en)
*
|
2009-09-14 |
2012-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating psoriasis
|
CN102666585B
(zh)
|
2009-11-24 |
2015-02-18 |
阿莱斯亚生物疗法股份有限公司 |
抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
JP5947727B2
(ja)
|
2010-01-20 |
2016-07-06 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ilt5抗体およびilt5結合抗体断片による免疫調節
|
CN102167741B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗TNF-α单克隆抗体、其制备方法及用途
|
US20110229921A1
(en)
|
2010-03-18 |
2011-09-22 |
Abbott Laboratories |
METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
|
CN107596365A
(zh)
|
2010-06-18 |
2018-01-19 |
埃克斯生物科技公司 |
关节炎治疗
|
WO2011163558A1
(en)
|
2010-06-25 |
2011-12-29 |
Abbott Laboratories |
Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
|
KR101910760B1
(ko)
|
2010-08-23 |
2018-10-22 |
엑스바이오테크, 인크. |
종양성 질병들에 대한 치료
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
US20120115244A1
(en)
|
2010-11-09 |
2012-05-10 |
Abbott Laboratories |
Materials and methods for immunoassay of pterins
|
CN102539778A
(zh)
*
|
2010-12-24 |
2012-07-04 |
北京义翘神州生物技术有限公司 |
一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
|
US20140051586A1
(en)
*
|
2011-01-25 |
2014-02-20 |
Ignacio Pino |
High-throughput methods to produce, validate and characterize mmabs
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
RU2622021C2
(ru)
|
2011-09-23 |
2017-06-08 |
ИксБиотеч, Инк. |
Лечение кахексии
|
US8993248B2
(en)
|
2011-12-31 |
2015-03-31 |
Abbott Laboratories |
Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
|
CA2862739A1
(en)
|
2012-02-22 |
2013-08-29 |
Alethia Biotherapeutics Inc. |
Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
EP2968550B1
(de)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
SG10202001779UA
(en)
|
2015-01-20 |
2020-04-29 |
Igm Biosciences Inc |
Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
CA3053231A1
(en)
|
2017-02-16 |
2018-08-23 |
Xbiotech Inc. |
Treatment of hidradenitis suppurativa
|
CN107903323B
(zh)
*
|
2017-11-15 |
2020-04-17 |
中国药科大学 |
抗hTNF-α全人源抗体及其用途
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
WO2020254861A1
(en)
|
2019-06-19 |
2020-12-24 |
Ovatrition Ltd. |
Antibody-mediated neutralization of beta-lactamases
|